New Antibiotics Show Promise in Fight Against Drug-Resistant Gonorrhea

The landscape of gonorrhea treatment is shifting, offering a glimmer of hope against a sexually transmitted infection that has grown increasingly resistant to existing medications. In December, the U.S. Food and Drug Administration approved two new oral antibiotics – gepotidacin (Blujepa) and zoliflodacin (Nuzolvence) – marking the first new approvals in decades to address this growing public health challenge. These approvals arrive at a critical time, as Neisseria gonorrhoeae, the bacterium that causes gonorrhea, continues to develop resistance to commonly used antibiotics, threatening the effectiveness of current treatment protocols.

A Rising Tide of Resistance

Gonorrhea affects millions globally each year. The World Health Organization estimates over 82 million new cases in 2020 alone. In the United States, the Centers for Disease Control and Prevention (CDC) estimates over 1.5 million new infections annually, classifying drug-resistant gonorrhea as an “urgent public health threat.” For years, ceftriaxone has been the cornerstone of gonorrhea treatment, often administered as a single injection. However, increasing resistance to ceftriaxone is eroding its effectiveness, prompting the urgent need for alternative therapies.

How the New Drugs Work

Blujepa (gepotidacin) was initially approved in March 2025 for uncomplicated urinary tract infections, and has now received approval for uncomplicated urogenital gonorrhea in patients 12 years and older weighing at least 99 pounds. It’s intended for employ when limited treatment options are available due to safety concerns. Nuzolvence (zoliflodacin) is a single-dose oral treatment approved for uncomplicated urogenital gonorrhea in adults and children 12 years and older weighing at least 77 pounds. Both medications offer a convenient oral alternative to the traditional injectable ceftriaxone.

Clinical trials demonstrated promising results. Gepotidacin showed a microbiological cure rate of 92.6% in phase 3 trials, while zoliflodacin achieved a 90.9% cure rate according to Healio. These rates suggest both drugs are highly effective in eradicating the infection, but ongoing surveillance will be crucial to monitor for the emergence of resistance.

Navigating the Path Forward: Prudent Use and Ongoing Research

The arrival of these new antibiotics doesn’t signal the complete of the fight against gonorrhea. Experts emphasize the importance of judicious use to prevent the development of further resistance. “Clinicians should use the new antibiotics when they would be an appropriate choice for the patient they are treating,” explains Amesh Adalja, MD, FIDSA, an infectious disease specialist at the Johns Hopkins Center for Health Security. However, he cautions that “if zoliflodacin and gepotidacin are used injudiciously, gonorrhea will do its thing: build resistance to them.”

The question of whether to reserve these new antibiotics for cases where ceftriaxone has failed, or to use them more broadly, is a subject of ongoing debate. Jodie A. Dionne, MD, MSPH, associate professor of medicine at The University of Alabama at Birmingham, anticipates that the CDC and Infectious Diseases Society of America will update their treatment guidelines to incorporate these new options.

The Role of Legislative Incentives

Addressing antimicrobial resistance requires a multi-faceted approach, including incentivizing the development of new drugs. The PASTEUR Act, proposed federal legislation, aims to do just that. This legislation proposes a novel funding model, often likened to a “Netflix-style” subscription, where the government would make annual payments to pharmaceutical companies to ensure access to new antimicrobials, regardless of their usage volume as outlined by the Infectious Diseases Society of America. This approach aims to decouple revenue from sales volume, encouraging investment in antibiotic research and development.

Beyond Antibiotics: The Search for Alternative Prevention Strategies

While new antibiotics offer a crucial tool in combating gonorrhea, they are not a panacea. Recent research has highlighted the challenges of developing alternative prevention strategies. A recent trial found that a meningococcal B vaccine (Bexsero) did not reduce the incidence of gonorrhea as reported by Healio, dashing hopes for a vaccine-based approach. Similarly, doxycycline post-exposure prophylaxis (doxy-PEP), a strategy involving taking doxycycline after unprotected sex, has shown limited effectiveness against gonorrhea.

What to Expect in the Coming Months

The introduction of gepotidacin and zoliflodacin represents a significant step forward in the fight against gonorrhea. However, ongoing surveillance, prudent antibiotic stewardship, and continued research into new prevention strategies are essential to stay ahead of this evolving threat. Clinicians should remain vigilant for signs of resistance and adhere to updated treatment guidelines as they grow available. The development of new antibiotics is a continuous process, and the need for innovative solutions remains paramount.

Amesh Adalja, MD, FIDSA, can be reached at [email protected].
Jodie A. Dionne, MD, MSPH, can be reached at [email protected].